Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever: https://g.foolcdn.com/editorial/images/772465/investment-advisor-getty.jpg
2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever

Income-seeking investors have to make an important choice when shopping for stocks to buy. Shares of companies that are likely to raise their dividend payouts at a rapid pace tend to offer low

2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever: https://g.foolcdn.com/editorial/images/772465/investment-advisor-getty.jpg
2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever

Income-seeking investors have to make an important choice when shopping for stocks to buy. Shares of companies that are likely to raise their dividend payouts at a rapid pace tend to offer low

Is Pfizer Stock the Biggest Bargain in the S&P 500?: https://g.foolcdn.com/editorial/images/772294/surprise-smartphone-news-stock-shock.jpg
Is Pfizer Stock the Biggest Bargain in the S&P 500?

Pfizer (NYSE: PFE) stock is relatively cheap. I can easily back up that claim. The big drugmaker's shares trade at lower forward earnings multiples than the S&P 500 and the S&P 500 healthcare

Is Pfizer Stock the Biggest Bargain in the S&P 500?: https://g.foolcdn.com/editorial/images/772294/surprise-smartphone-news-stock-shock.jpg
Is Pfizer Stock the Biggest Bargain in the S&P 500?

Pfizer (NYSE: PFE) stock is relatively cheap. I can easily back up that claim. The big drugmaker's shares trade at lower forward earnings multiples than the S&P 500 and the S&P 500 healthcare

Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.: https://g.foolcdn.com/editorial/images/772470/gettyimages-1273241342.jpg
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.

Cathie Wood is known for her investments in disruptive technologies that are changing or have the potential to change the way things are done. She's built a solid reputation as a stock picker

Agave Ridge Behavioral Hospital Hosts Ceremony to Celebrate Grand Opening: https://mms.businesswire.com/media/20240411986178/en/2096213/5/ACHC_Agave_Ridge_Mesa_Photo.jpg
Agave Ridge Behavioral Hospital Hosts Ceremony to Celebrate Grand Opening


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest acute care hospital, Agave Ridge Behavioral Hospital, located at 3322 S. Ellsworth Road, in Mesa, Arizona. A

Vertex Pharmaceuticals: Buy, Sell, or Hold?: https://g.foolcdn.com/editorial/images/772095/doctor-giving-a-patient-medication.jpg
Vertex Pharmaceuticals: Buy, Sell, or Hold?

Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now

Vertex Pharmaceuticals: Buy, Sell, or Hold?: https://g.foolcdn.com/editorial/images/772095/doctor-giving-a-patient-medication.jpg
Vertex Pharmaceuticals: Buy, Sell, or Hold?

Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now

Vertex Pharmaceuticals: Buy, Sell, or Hold?: https://g.foolcdn.com/editorial/images/772095/doctor-giving-a-patient-medication.jpg
Vertex Pharmaceuticals: Buy, Sell, or Hold?

Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now

Is Amgen Stock a Buy?: https://g.foolcdn.com/editorial/images/772093/a-team-of-scientists-reviewing-results-in-a-lab.jpg
Is Amgen Stock a Buy?

Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks to

Is Amgen Stock a Buy?: https://g.foolcdn.com/editorial/images/772093/a-team-of-scientists-reviewing-results-in-a-lab.jpg
Is Amgen Stock a Buy?

Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks to

Is Amgen Stock a Buy?: https://g.foolcdn.com/editorial/images/772093/a-team-of-scientists-reviewing-results-in-a-lab.jpg
Is Amgen Stock a Buy?

Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks to

EQS-News: MorphoSys’ Management Board and Supervisory Board  Recommend Shareholders Accept Public Takeover Offer by  Novartis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
EQS-News: MorphoSys’ Management Board and Supervisory Board  Recommend Shareholders Accept Public Takeover Offer by  Novartis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.: https://g.foolcdn.com/editorial/images/772266/doctor-and-patient-in-a-hospital-room.jpg
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.

There are plenty of things to buy with $200. But what about investing in a company that can grow your capital for years? Though some people believe they need millions, or at least thousands, to

EQS-News: Gerresheimer makes solid start to the financial year 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer makes solid start to the financial year 2024
EQS-News: Gerresheimer makes solid start to the financial year 2024
2 Under-the-Radar Growth Stocks to Consider: https://g.foolcdn.com/editorial/images/772261/patient-taking-medicine.jpg
2 Under-the-Radar Growth Stocks to Consider

Exciting growth stocks are highly coveted, but some fly under the radar for various reasons. And this gives astute investors the opportunity to pounce before their shares rise significantly.

Mid-cap

QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay: https://mms.businesswire.com/media/20240410125315/en/2093757/5/7600_front_transparent.jpg
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay


QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a

Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?: https://g.foolcdn.com/editorial/images/772084/people-agreeing-on-a-deal.jpg
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?

Johnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of

Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?: https://g.foolcdn.com/editorial/images/772084/people-agreeing-on-a-deal.jpg
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?

Johnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of

Where Will Pfizer Stock Be in 10 Years?: https://g.foolcdn.com/editorial/images/772094/businessperson-giving-a-presentation.jpg
Where Will Pfizer Stock Be in 10 Years?

Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have

Where Will Pfizer Stock Be in 10 Years?: https://g.foolcdn.com/editorial/images/772094/businessperson-giving-a-presentation.jpg
Where Will Pfizer Stock Be in 10 Years?

Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have

This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?: https://g.foolcdn.com/editorial/images/771663/physician-giving-medicine-to-elderly-patient.jpg
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive

This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?: https://g.foolcdn.com/editorial/images/771663/physician-giving-medicine-to-elderly-patient.jpg
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive

This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?: https://g.foolcdn.com/editorial/images/771663/physician-giving-medicine-to-elderly-patient.jpg
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive